RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines
Go back to RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines| IntelGenx Technologies Corp. (AMEX: IGXT) | Delayed: 0.17 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.17 | 52 Week High | $1.00 | |||
| Open | $0.00 | 52 Week Low | $0.37 | |||
| Day High | $0.17 | P/E | N/A | |||
| Day Low | $0.17 | EPS | $-0.03 | |||
| Volume | 1,130,000 | |||||
| REDHILL BIO SP ADS (NASDAQ: RDHL) | Delayed: 0.57 -0.02 (3.39%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.59 | 52 Week High | $16.54 | |||
| Open | $0.58 | 52 Week Low | $8.10 | |||
| Day High | $0.59 | P/E | N/A | |||
| Day Low | $0.56 | EPS | $0.00 | |||
| Volume | 80,584 | |||||
